Dilated Cardiomyopathy – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Dilated Cardiomyopathy – Pipeline Review, H2 2020’, provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy

– The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects

– The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dilated Cardiomyopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Berlin Cures Holding AG

Celixir Ltd

CellServe GmbH

Heartseed Inc

Help Therapeutics

iHeart Japan Corp

Martin Pharmaceuticals Inc

MyoKardia Inc

Olagenesis Corp

Pfizer Inc

Renovacor Inc

Shionogi & Co Ltd

Table of Contents

Table of Contents

Introduction

Dilated Cardiomyopathy - Overview

Dilated Cardiomyopathy - Therapeutics Development

Dilated Cardiomyopathy - Therapeutics Assessment

Dilated Cardiomyopathy - Companies Involved in Therapeutics Development

Dilated Cardiomyopathy - Drug Profiles

Dilated Cardiomyopathy - Dormant Projects

Dilated Cardiomyopathy - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Dilated Cardiomyopathy – Pipeline by Berlin Cures Holding AG, H2 2020

Dilated Cardiomyopathy – Pipeline by Celixir Ltd, H2 2020

Dilated Cardiomyopathy – Pipeline by CellServe GmbH, H2 2020

Dilated Cardiomyopathy – Pipeline by Heartseed Inc, H2 2020

Dilated Cardiomyopathy – Pipeline by Help Therapeutics, H2 2020

Dilated Cardiomyopathy – Pipeline by iHeart Japan Corp, H2 2020

Dilated Cardiomyopathy – Pipeline by Martin Pharmaceuticals Inc, H2 2020

Dilated Cardiomyopathy – Pipeline by MyoKardia Inc, H2 2020

Dilated Cardiomyopathy – Pipeline by Olagenesis Corp, H2 2020

Dilated Cardiomyopathy – Pipeline by Pfizer Inc, H2 2020

Dilated Cardiomyopathy – Pipeline by Renovacor Inc, H2 2020

Dilated Cardiomyopathy – Pipeline by Shionogi & Co Ltd, H2 2020

Dilated Cardiomyopathy – Dormant Projects, H2 2020

List of Figures

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports